NYSE$GMED

Globus Medical Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Briefing

Globus Medical's financial results increased following the merger with NuVasive.

Globus Medical reported a 51.0% increase in worldwide net sales to $383.6 million for Q3 2023, driven by the recent merger with NuVasive. GAAP net income was $1.0 million, with a diluted EPS of $0.01, while non-GAAP diluted EPS reached $0.57. The company has increased its full year revenue guidance to $1.55 billion and reaffirmed its non-GAAP EPS guidance.

  • Worldwide net sales increased by 51.0% to $383.6 million.
  • GAAP net income was $1.0 million, a 97.9% decrease year-over-year.
  • GAAP diluted EPS was $0.01, while non-GAAP diluted EPS was $0.57.
  • Non-GAAP adjusted EBITDA was $112.9 million, representing 29.4% of net sales.

Headline financials

Total Revenue

$384M

Previous: $254M+51.0%
EPS (adj)

$0.57

Previous: $0.50+14.0%
Adjusted EBITDA

$113M

Previous: $82.8M+36.3%
Adjusted EBITDA Margin

29.4%

No prior period
Capital Expenditures

-$55.4M

Previous: -$55.7M+0.6%
Free Cash Flow

-$54.4M

Previous: -$8.28M-557.3%
Net Income

$998K

Previous: $47.4M-97.9%
Operating Income

$404K

Previous: $59.7M-99.3%
Gross Profit

$248M

Previous: $189M+31.6%
Cash & Equivalents

$280M

Previous: $134M+108.3%
Total Assets

$5.36B

Previous: $1.98B+171.0%
R&D Expense

$29.3M

No prior period
Stock-Based Comp

$22.8M

Previous: $8.31M+173.7%

Revenue & EPS history

Globus Medical · Revenue · Quarterly

$384M

Q3 2023+51%vs Q3 2022
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Revenue by segment

Globus Medical · $375M total across 2 segments · Q3 2023

  • Musculoskeletal Solutions
    $347M+51.0%
  • Enabling Technologies
    $27.7M+14.8%

Forward guidance

The Company increased its full year fiscal 2023 revenue guidance to $1.55 billion and reaffirmed non-GAAP fully diluted earnings per share guidance of $2.30.

Tailwinds

  • Increased full year fiscal 2023 revenue guidance to $1.55 billion.
  • Reaffirmed non-GAAP fully diluted earnings per share guidance of $2.30.
  • Completed merger with NuVasive, Inc.
  • Focused on executing integration plan.
  • Long-term business plan remains unchanged.

Headwinds

  • Risks associated with the integration of NuVasive business.
  • Health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic.
  • Factors affecting quarterly results.
  • Ability to manage growth and sustain profitability.
  • Demand for products and ability to compete successfully.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+0.8%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+0.9%

Avg return

30 days after

57%

34 / 60 earnings

Positive

+36.0%

Q3 2025

Best reaction

-23.0%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-5.1%-14.6%-10.4%
Q4 2025+4.6%+2.1%-8.8%
Q3 2025+36.0%+37.3%+47.6%
Q1 2025-23.0%-19.7%-17.3%
Q4 2024-4.6%-4.9%-12.5%
Q3 2024+10.7%+8.2%+11.2%
Q2 2024+4.0%+8.0%+4.4%
Q1 2024+22.8%+28.7%+31.6%
Q4 2023+2.2%+4.6%-3.1%
Q3 2023-1.4%-5.1%-2.5%
Q2 2023-5.0%-4.8%-9.1%
Q1 2023+2.9%-0.3%-1.8%
Q4 2022-1.2%-21.9%-29.2%
Q3 2022-4.2%+9.4%+11.5%
Q2 2022+5.4%+6.9%-2.4%
Q1 2022+0.1%+5.2%+0.1%
Q4 2021-3.1%-3.7%+1.3%
Q3 2021+0.2%-4.3%-19.4%
Q2 2021-3.3%-3.0%+1.3%
Q1 2021+3.1%+3.0%-0.9%
Q4 2020-5.7%-5.2%-10.2%
Q3 2020+2.4%+3.5%+16.9%
Q2 2020+18.5%+13.4%+13.3%
Q1 2020+8.1%+0.6%+21.4%
Q4 2019-2.1%-9.7%-29.0%
Q3 2019+3.6%+4.2%+8.2%
Q2 2019+9.9%+6.1%+12.0%
Q1 2019-1.9%-2.0%-11.0%
Q4 2018+0.2%-2.2%-0.3%
Q3 2018-8.7%-9.9%-19.4%
Q2 2018+4.7%+1.7%+3.5%
Q1 2018-3.4%+0.7%+12.6%
Q4 2017+0.5%-1.8%+2.2%
Q3 2017+9.8%+19.7%+24.3%
Q2 2017-5.2%-3.7%-1.7%
Q1 2017+4.9%+1.0%+4.7%
Q4 2016-3.1%-2.1%+2.5%
Q3 2016-5.6%-4.9%+7.1%
Q2 2016-14.3%-11.7%-13.1%
Q1 2016-9.4%
Q4 2015+4.2%
Q3 2015+12.3%
Q2 2015+2.5%
Q1 2015+4.8%
Q4 2014-0.9%
Q3 2014+7.0%
Q2 2014-16.8%
Q1 2014+6.1%
Q4 2013+1.4%
Q3 2013+7.1%
Q2 2013+2.3%
Q1 2013+7.9%
Q1 2011+0.4%
Q4 2010+0.4%
Q4 2012+5.8%
Q3 2011-20.7%
Q3 2012-16.2%
Q4 2011-0.7%
Q2 2011-0.7%
Q2 2012+0.0%
Q1 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro